116,686 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 116,686 shares of the biopharmaceutical company’s stock, valued at approximately $10,778,000.

Other institutional investors also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.7 %

GILD opened at $111.16 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm’s fifty day moving average price is $105.08 and its two-hundred day moving average price is $94.58. The company has a market capitalization of $138.43 billion, a P/E ratio of 300.43, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 302,785 shares of company stock worth $30,503,250. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GILD shares. Royal Bank of Canada raised their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.